139 related articles for article (PubMed ID: 37572539)
21. Modulation of FLT3-ITD and CDK9 in acute myeloid leukaemia cells by novel proteolysis targeting chimera (PROTAC).
Řezníčková E; Krajčovičová S; Peřina M; Kovalová M; Soural M; Kryštof V
Eur J Med Chem; 2022 Dec; 243():114792. PubMed ID: 36191408
[TBL] [Abstract][Full Text] [Related]
22. Cyclin-dependent kinase (CDK) 9 and 4/6 inhibitors in acute myeloid leukemia (AML): a promising therapeutic approach.
Lee DJ; Zeidner JF
Expert Opin Investig Drugs; 2019 Nov; 28(11):989-1001. PubMed ID: 31612739
[No Abstract] [Full Text] [Related]
23. Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies.
Barlaam B; Casella R; Cidado J; Cook C; De Savi C; Dishington A; Donald CS; Drew L; Ferguson AD; Ferguson D; Glossop S; Grebe T; Gu C; Hande S; Hawkins J; Hird AW; Holmes J; Horstick J; Jiang Y; Lamb ML; McGuire TM; Moore JE; O'Connell N; Pike A; Pike KG; Proia T; Roberts B; San Martin M; Sarkar U; Shao W; Stead D; Sumner N; Thakur K; Vasbinder MM; Varnes JG; Wang J; Wang L; Wu D; Wu L; Yang B; Yao T
J Med Chem; 2020 Dec; 63(24):15564-15590. PubMed ID: 33306391
[TBL] [Abstract][Full Text] [Related]
24. Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1.
Lemke J; von Karstedt S; Abd El Hay M; Conti A; Arce F; Montinaro A; Papenfuss K; El-Bahrawy MA; Walczak H
Cell Death Differ; 2014 Mar; 21(3):491-502. PubMed ID: 24362439
[TBL] [Abstract][Full Text] [Related]
25. Discovery of selective CDK9 degraders with enhancing antiproliferative activity through PROTAC conversion.
Qiu X; Li Y; Yu B; Ren J; Huang H; Wang M; Ding H; Li Z; Wang J; Bian J
Eur J Med Chem; 2021 Feb; 211():113091. PubMed ID: 33338869
[TBL] [Abstract][Full Text] [Related]
26. Cyclin-dependent kinase 9 activity regulates neutrophil spontaneous apoptosis.
Wang K; Hampson P; Hazeldine J; Krystof V; Strnad M; Pechan P; M J
PLoS One; 2012; 7(1):e30128. PubMed ID: 22276149
[TBL] [Abstract][Full Text] [Related]
27. Antitumor effects of cyclin dependent kinase 9 inhibition in esophageal adenocarcinoma.
Tong Z; Chatterjee D; Deng D; Veeranki O; Mejia A; Ajani JA; Hofstetter W; Lin S; Guha S; Kopetz S; Krishnan S; Maru D
Oncotarget; 2017 Apr; 8(17):28696-28710. PubMed ID: 28404924
[TBL] [Abstract][Full Text] [Related]
28. Repression of Mcl-1 expression by the CDC7/CDK9 inhibitor PHA-767491 overcomes bone marrow stroma-mediated drug resistance in AML.
O' Reilly E; Dhami SPS; Baev DV; Ortutay C; Halpin-McCormick A; Morrell R; Santocanale C; Samali A; Quinn J; O'Dwyer ME; Szegezdi E
Sci Rep; 2018 Oct; 8(1):15752. PubMed ID: 30361682
[TBL] [Abstract][Full Text] [Related]
29. Wogonin and related natural flavones are inhibitors of CDK9 that induce apoptosis in cancer cells by transcriptional suppression of Mcl-1.
Polier G; Ding J; Konkimalla BV; Eick D; Ribeiro N; Köhler R; Giaisi M; Efferth T; Desaubry L; Krammer PH; Li-Weber M
Cell Death Dis; 2011 Jul; 2(7):e182. PubMed ID: 21776020
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.
Luedtke DA; Su Y; Ma J; Li X; Buck SA; Edwards H; Polin L; Kushner J; Dzinic SH; White K; Lin H; Taub JW; Ge Y
Signal Transduct Target Ther; 2020 Feb; 5(1):17. PubMed ID: 32296028
[TBL] [Abstract][Full Text] [Related]
31. Mechanisms of action of a dual Cdc7/Cdk9 kinase inhibitor against quiescent and proliferating CLL cells.
Natoni A; Murillo LS; Kliszczak AE; Catherwood MA; Montagnoli A; Samali A; O'Dwyer M; Santocanale C
Mol Cancer Ther; 2011 Sep; 10(9):1624-34. PubMed ID: 21768328
[TBL] [Abstract][Full Text] [Related]
32. Current and emerging therapies for patients with acute myeloid leukemia: a focus on MCL-1 and the CDK9 pathway.
Lyle L; Daver N
Am J Manag Care; 2018 Aug; 24(16 Suppl):S356-S365. PubMed ID: 30132679
[TBL] [Abstract][Full Text] [Related]
33. Ligand- and structure-based identification of novel CDK9 inhibitors for the potential treatment of leukemia.
Zhang H; Huang J; Chen R; Cai H; Chen Y; He S; Xu J; Zhang J; Wang L
Bioorg Med Chem; 2022 Oct; 72():116994. PubMed ID: 36087428
[TBL] [Abstract][Full Text] [Related]
34. CDK9 Inhibitor Induces Apoptosis, Autophagy, and Suppression of Tumor Growth in Adult T-Cell Leukemia/Lymphoma.
Kato N; Kozako T; Ohsugi T; Uchida Y; Yoshimitsu M; Ishitsuka K; Aikawa A; Honda SI
Biol Pharm Bull; 2023; 46(9):1269-1276. PubMed ID: 37661406
[TBL] [Abstract][Full Text] [Related]
35. Structure-based design of highly selective 2,4,5-trisubstituted pyrimidine CDK9 inhibitors as anti-cancer agents.
Shao H; Foley DW; Huang S; Abbas AY; Lam F; Gershkovich P; Bradshaw TD; Pepper C; Fischer PM; Wang S
Eur J Med Chem; 2021 Mar; 214():113244. PubMed ID: 33581551
[TBL] [Abstract][Full Text] [Related]
36. O-methylated flavonol as a multi-kinase inhibitor of leukemogenic kinases exhibits a potential treatment for acute myeloid leukemia.
Yen SC; Wu YW; Huang CC; Chao MW; Tu HJ; Chen LC; Lin TE; Sung TY; Tseng HJ; Chu JC; Huang WJ; Yang CR; HuangFu WC; Pan SL; Hsu KC
Phytomedicine; 2022 Jun; 100():154061. PubMed ID: 35364561
[TBL] [Abstract][Full Text] [Related]
37. Antitumor action of CDK inhibitor LS-007 as a single agent and in combination with ABT-199 against human acute leukemia cells.
Xie S; Jiang H; Zhai XW; Wei F; Wang SD; Ding J; Chen Y
Acta Pharmacol Sin; 2016 Nov; 37(11):1481-1489. PubMed ID: 27569395
[TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and biological evaluation of novel 4,4'-bipyridine derivatives acting as CDK9-Cyclin T1 protein-protein interaction inhibitors against triple-negative breast cancer.
Gao G; Li J; Cao Y; Li X; Qian Y; Wang X; Li M; Qiu Y; Wu T; Wang L; Fang M
Eur J Med Chem; 2023 Dec; 261():115858. PubMed ID: 37837671
[TBL] [Abstract][Full Text] [Related]
39. Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
Whittaker SR; Barlow C; Martin MP; Mancusi C; Wagner S; Self A; Barrie E; Te Poele R; Sharp S; Brown N; Wilson S; Jackson W; Fischer PM; Clarke PA; Walton MI; McDonald E; Blagg J; Noble M; Garrett MD; Workman P
Mol Oncol; 2018 Mar; 12(3):287-304. PubMed ID: 29063678
[TBL] [Abstract][Full Text] [Related]
40. Changing for the Better: Discovery of the Highly Potent and Selective CDK9 Inhibitor VIP152 Suitable for Once Weekly Intravenous Dosing for the Treatment of Cancer.
Lücking U; Kosemund D; Böhnke N; Lienau P; Siemeister G; Denner K; Bohlmann R; Briem H; Terebesi I; Bömer U; Schäfer M; Ince S; Mumberg D; Scholz A; Izumi R; Hwang S; von Nussbaum F
J Med Chem; 2021 Aug; 64(15):11651-11674. PubMed ID: 34264057
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
